Thomas R Radomski1,2, Yan Huang1,3, Seo Young Park1, Florentina E Sileanu1, Carolyn T Thorpe2,4, Joshua M Thorpe2,4, Michael J Fine1,2, Walid F Gellad1,2. 1. Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 2. Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. 3. UPMC Center for High-Value Health Care, UPMC Insurance Services Division, Pittsburgh, Pennsylvania. 4. Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina.
Abstract
BACKGROUND/ OBJECTIVES: Prostate-specific antigen (PSA) screening can be of low value in older adults. Our objective was to quantify the prevalence and variation of low-value PSA screening across the Veterans Health Administration (VA), which has instituted programs to reduce low-value care. DESIGN: Retrospective cohort. SETTING: VA administrative data, 2014 to 2015. PARTICIPANTS: National random sample (N = 214 480) of male veterans, aged 75 years or older. MEASUREMENTS: We defined PSA screening in men aged 75 years or older without a history of prostate cancer as low value, per established definitions in Medicare. We calculated screening rates overall and by VA Medical Center (VAMC), adjusting for patient and VAMC-level factors. We characterized variation across VAMCs using the adjusted median odds ratio (OR) and compared the adjusted OR of screening between VAMCs in different deciles of low-value screening rates. In separate sensitivity analyses, we assessed screening in veterans at greatest risk of 1-year mortality and among veterans after excluding those who underwent prostatectomy, had a prior PSA elevation, or had a clinical indication for testing. RESULTS: Overall, 37 867 (17.7%) of veterans underwent low-value PSA screening (VAMC range = 3.3%-38.2%). The adjusted median OR was 1.88, meaning the median odds of screening would increase by 88% were a veteran to transfer his care to a VAMC with higher screening rates. Veterans at VAMCs in the top decile had an adjusted OR of 12.9 (95% confidence interval = 11.0-15.2) compared to those veterans in the lowest decile. Among veterans with the greatest mortality risk (n = 23 377), 3496 (15.0%) underwent screening (VAMC range = 1.7%-46.3%). After excluding veterans with a prior prostatectomy, PSA elevation, or a potential clinical indication, 31 556 (14.7%) underwent screening (VAMC range = 2.0%-49.9%). CONCLUSIONS: In a national cohort of older veterans, more than one in six received low-value PSA screening, with greater than 10-fold variation across VAMCs and high rates of screening among those with the greatest mortality risk. J Am Geriatr Soc 67:1922-1927, 2019. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND/ OBJECTIVES:Prostate-specific antigen (PSA) screening can be of low value in older adults. Our objective was to quantify the prevalence and variation of low-value PSA screening across the Veterans Health Administration (VA), which has instituted programs to reduce low-value care. DESIGN: Retrospective cohort. SETTING: VA administrative data, 2014 to 2015. PARTICIPANTS: National random sample (N = 214 480) of male veterans, aged 75 years or older. MEASUREMENTS: We defined PSA screening in men aged 75 years or older without a history of prostate cancer as low value, per established definitions in Medicare. We calculated screening rates overall and by VA Medical Center (VAMC), adjusting for patient and VAMC-level factors. We characterized variation across VAMCs using the adjusted median odds ratio (OR) and compared the adjusted OR of screening between VAMCs in different deciles of low-value screening rates. In separate sensitivity analyses, we assessed screening in veterans at greatest risk of 1-year mortality and among veterans after excluding those who underwent prostatectomy, had a prior PSA elevation, or had a clinical indication for testing. RESULTS: Overall, 37 867 (17.7%) of veterans underwent low-value PSA screening (VAMC range = 3.3%-38.2%). The adjusted median OR was 1.88, meaning the median odds of screening would increase by 88% were a veteran to transfer his care to a VAMC with higher screening rates. Veterans at VAMCs in the top decile had an adjusted OR of 12.9 (95% confidence interval = 11.0-15.2) compared to those veterans in the lowest decile. Among veterans with the greatest mortality risk (n = 23 377), 3496 (15.0%) underwent screening (VAMC range = 1.7%-46.3%). After excluding veterans with a prior prostatectomy, PSA elevation, or a potential clinical indication, 31 556 (14.7%) underwent screening (VAMC range = 2.0%-49.9%). CONCLUSIONS: In a national cohort of older veterans, more than one in six received low-value PSA screening, with greater than 10-fold variation across VAMCs and high rates of screening among those with the greatest mortality risk. J Am Geriatr Soc 67:1922-1927, 2019. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
Entities:
Keywords:
low-value care; prostate cancer screening; veterans
Authors: H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman Journal: J Urol Date: 2013-05-06 Impact factor: 7.450
Authors: David C Grossman; Susan J Curry; Douglas K Owens; Kirsten Bibbins-Domingo; Aaron B Caughey; Karina W Davidson; Chyke A Doubeni; Mark Ebell; John W Epling; Alex R Kemper; Alex H Krist; Martha Kubik; C Seth Landefeld; Carol M Mangione; Michael Silverstein; Melissa A Simon; Albert L Siu; Chien-Wen Tseng Journal: JAMA Date: 2018-05-08 Impact factor: 56.272
Authors: Thomas R Radomski; Yan Huang; Seo Young Park; Florentina E Sileanu; Carolyn T Thorpe; Joshua M Thorpe; Michael J Fine; Walid F Gellad Journal: J Am Geriatr Soc Date: 2019-07-05 Impact factor: 5.562
Authors: Thomas R Radomski; Yan Huang; Seo Young Park; Florentina E Sileanu; Carolyn T Thorpe; Joshua M Thorpe; Michael J Fine; Walid F Gellad Journal: J Am Geriatr Soc Date: 2019-07-05 Impact factor: 5.562
Authors: Justine P Enns; Craig E Pollack; Cynthia M Boyd; Jacqueline Massare; Nancy L Schoenborn Journal: J Gen Intern Med Date: 2021-09-20 Impact factor: 6.473
Authors: Patrick P Coll; Beatriz Korc-Grodzicki; Benjamin T Ristau; Armin Shahrokni; Alexander Koshy; Olga T Filippova; Imran Ali Journal: J Am Geriatr Soc Date: 2020-09-03 Impact factor: 7.538
Authors: Linnaea Schuttner; Bjarni Haraldsson; Charles Maynard; Christian D Helfrich; Ashok Reddy; Toral Parikh; Karin M Nelson; Edwin Wong Journal: JAMA Netw Open Date: 2021-10-01
Authors: Thomas R Radomski; Robert Feldman; Yan Huang; Florentina E Sileanu; Carolyn T Thorpe; Joshua M Thorpe; Michael J Fine; Walid F Gellad Journal: JAMA Netw Open Date: 2020-09-01
Authors: Ravi B Parikh; Kyle W Robinson; Sumedha Chhatre; Elina Medvedeva; John P Cashy; Shika Veera; Joshua M Bauml; Tito Fojo; Amol S Navathe; S Bruce Malkowicz; Ronac Mamtani; Ravishankar Jayadevappa Journal: JAMA Netw Open Date: 2020-09-01